(Lung Cancer) What Is the 5-Year Overall Survival Rate with anti-PD-1 antibody?
(Lung Cancer) What Is the 5-Year Overall Survival Rate with anti-PD-1 antibody?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) What Is the 5-Year Overall Survival Rate with anti-PD-1 antibody?
- October 12, 2019
- 2 min read
On September 10, 2019, Bristol-Myers Squibb announced pooled five-year follow-up analysis results for previously treated advanced non-small cell lung cancer patients receiving anti-PD-1 antibody anti-PD-1 antibody monotherapy.
This pooled analysis was based on the Phase III clinical trials CheckMate-017 and CheckMate-057. Both trials enrolled non-small cell lung cancer patients who had progressed after first-line treatment. Patients were randomized 1:1 into the anti-PD-1 antibody monotherapy group (3 mg/kg every two weeks) and the docetaxel monotherapy group (75 mg/m2 every three weeks). The primary endpoint was overall survival. Additionally, the CheckMate-017 trial enrolled squamous cell carcinoma patients, while the CheckMate-057 trial enrolled non-squamous cell carcinoma patients.
The pooled analysis results showed that the primary endpoint 5-year overall survival rate was 13.4% for the anti-PD-1 antibody group / 2.6% for the docetaxel group. Subgroup analysis reported higher 5-year survival rates in the anti-PD-1 antibody group across the subgroups examined (literature data; for reference only).
For secondary endpoints, the objective response rate showed that approximately 32.2% of patients who responded to anti-PD-1 antibody maintained their response at year 5 / no patients in the docetaxel group maintained response at year 5. The median duration of response was 19.9 months / 5.6 months, respectively. Regarding safety, the adverse events observed in this analysis were consistent with the known safety profile from other clinical trials, with no new adverse events identified.
Based on this pooled analysis, Scott Gettinger concluded that previously treated advanced non-small cell lung cancer patients receiving anti-PD-1 antibody anti-PD-1 antibody monotherapy demonstrated significantly greater benefit compared to conventional chemotherapy, even with long-term treatment.
[Disclaimer] The clinical trial data and pharmaceutical information translated by "Medical Supporter" from overseas studies are not intended to encourage participation in clinical trials or use of new drugs. The translated materials are for reference only and do not constitute medication guidelines. Please consult with healthcare professionals, and refer to the original text below for accurate content.
Source: Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients
#LungCancer
-
Investigational drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.